The concept of in vivo airway tissue engineering

Philipp Jungebluth a, f, 1, Augustinus Bader b, h, Silvia Baiguera c, Susanne Möller a, Massimo Jaus c, Mei Ling Lim a, d, Kaj Fried d, Kristín Rós Kjartansdóttir a, Tetsuhiko Go c, Heike Nave e, Wolfgang Harringer f, Vanessa Lundin g, Ana I. Teixeira g, Paolo Macchiarini a, c, f, *

a ACTREM, Karolinska Institutet, Stockholm, Sweden
b Center for Biotechnology and Biomedicine, Cell Techniques and Applied Stem Cell Biology, University of Leipzig, Leipzig, Germany
c European Center of Thoracic Research (CERT), Florence, Italy
d Center for Oral Biology, Novum, Karolinska Institutet, Stockholm, Sweden
e Department of Anatomy and Cell Biology, Martin Luther University Faculty of Medicine, Halle (Saale), Germany
f Department of Thoracic and Cardiovascular Surgery, Klinikum Braunschweig, Germany
g Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden

ARTICLE INFO

Article history:
Received 5 February 2012
Accepted 4 March 2012
Available online 21 March 2012

Keywords:
Decellularized trachea
In vivo tissue engineering
Intraoperative seeding
Boosting therapy

ABSTRACT

We investigated whether decellularized pig tracheas could regenerate in vivo, without being recellularized before transplantation, using the own body as bioreactor. Decellularized pig tracheal scaffolds were intraoperative conditioned with mononuclear cells and growth and differentiation factors. During the postoperative period, the in situ regeneration was boosted by administering bioactive molecules to promote peripheral mobilization and differentiation of stem/progenitor cells and ultimately the regenerative process. Results revealed, after 2 weeks, a nearly normal trachea, with respiratory epithelium and a double-banded cartilage but without any mechanical differences compared to the native tissue. The growth factor administration resulted in a mobilization of progenitor and stem cells into the peripheral circulation and in an up-regulation of anti-apoptotic genes. Isolated stem/progenitor cells could be differentiated in vitro into several cell types, proving their multipotency. We provide evidence that the own body can be used as bioreactor to promote in vivo tissue engineering replacement. Moreover, we demonstrated the beneficial effect of additional pharmaceutical intervention for an improved engraftment of the transplant.

© 2012 Elsevier Ltd. All rights reserved.

1. Introduction

Although the vast majority of benign and malignant diseases of the trachea can be surgically cured, a safe and conventional surgical reconstruction is not always possible and these patients are treated with palliation alone [1]. Airway tissue engineering has proven its capability to repair tracheal defects of extensive length (>6 cm) in animals and in humans [2,3], by using decellularized natural scaffolds reseeded with stem cell-derived chondrocytes and respiratory cells via a bioreactor. This approach generates scaffolds that maintain their extracellular matrix (ECM), induce in vivo neoangiogenesis, and provide epithelial cell engraftment. Equally important, decellularized tracheal scaffolds have almost all characteristics of a native trachea, such as longitudinal flexibility, lateral rigidity, non-immunogenicity, air- and liquid tightness, biocompatibility, and least but not last, are resistant to bacterial colonization [3–6]. Although this regenerative approach outrivals previously published methods [7,8], it also requires extensive GMP laboratory facilities, in vitro cell culture and manipulation, specific manpower and know-how, and high costs which significantly limit its clinical translation worldwide.

To bypass these hurdles, and based on our initial reverse translational experience [9] we developed a new concept, the combined in vivo and in situ tissue engineering, which has passed the preclinical stage in a number of tissues such as skin and bone regeneration and is currently being evaluated in a human multicenter clinical trial [10]. This concept bases on the use of the own body as a natural bioreactor at a normotopic in situ positioning of the transplant. This reduces contamination risks, significantly shortens the processing time and costs, and combines the peritransplantation administration of bioactive molecules [11] to (e.g. granulocyte-colony stimulating factor) mobilize mesenchymal and...